Akzo Nobel Pharma “Rough Ride” In 2004 Offset By Partnering, R&D Potential
Executive Summary
Akzo Nobel hopes that partnering agreements and investment in R&D will help its pharmaceutical division weather the "rough ride" expected in 2004
You may also be interested in...
Organon to withdraw gepirone NDA
Organon is planning to withdraw the NDA for its antidepressant gepirone ER following the receipt of a second "not approvable" letter from FDA June 23. The company submitted additional data in December 2003, and planned to market the drug as Variza. FDA's response likely relates to efficacy concerns, which were cited in the first "not approvable" letter in April 2002. Organon had been counting on gepirone (along with the contraceptive Implanon) as one of two major launches in 2004 (1"The Pink Sheet" April 26, 2004, p. 15)...
Organon to withdraw gepirone NDA
Organon is planning to withdraw the NDA for its antidepressant gepirone ER following the receipt of a second "not approvable" letter from FDA June 23. The company submitted additional data in December 2003, and planned to market the drug as Variza. FDA's response likely relates to efficacy concerns, which were cited in the first "not approvable" letter in April 2002. Organon had been counting on gepirone (along with the contraceptive Implanon) as one of two major launches in 2004 (1"The Pink Sheet" April 26, 2004, p. 15)...
Organon Building New Quality Affairs Group; New Jersey Plant To Close
Organon plans to build a new quality affairs organization with a staff of 45-50 employees following the closure of its injectable drug manufacturing facility in West Orange, N.J